More young people are dying from toxic drugs, warns chief medical examiner
Dr. Nash Denic, Newfoundland and Labrador's chief medical examiner, says the drugs currently circulating on the streets cannot be trusted due to high toxicity. (Ted Dillon/CBC)
Teenagers as young as 14 years old are dying from drug overdoses in recent "gut-wrenching" incidents, says Newfoundland and Labrador's chief medical examiner.
Dr. Nash Denic joined the RCMP in a press conference Wednesday. Cocaine is now the leading drug responsible for overdose deaths in Newfoundland and Labrador, according to the RCMP.
It comes a day after CBC News published a months-long investigation exposing the province's deadly cocaine problem and tracking the drugs from Colombia to Canada, and eventually to Labrador communities.
The Office of the Chief Medical Examiner reported 61 drug-related deaths in the province last year, 34 of them from cocaine. CBC News has reported deaths from cocaine have spiked since 2014.
"The drugs currently on the market cannot be trusted," Denic said, referring both to cocaine and counterfeit drugs that have gained popularity among young people recently.
Some of those substances include pressed pills made of bromazolam, methamphetamine and MDMA, also known as ecstasy, disguised as Xanax; as well as fake Dilaudid composed of protonitazine, a synthetic opioid over 20 times more potent than fentanyl.
"If you can just imagine, imagine the two grains of salt-size fentanyl is enough to produce death in individuals, you can only imagine how much you need of the new opioid," said Denic.
Denic also told reporters some youth are trying drugs at a very young age, so they wouldn't have any built-up tolerance. Even if they did, Denic says, new opioids such as nitazenes — which are sometimes cut into other drugs — are extremely toxic.
WATCH | Police say cocaine is getting stronger in N.L.:
He says the individuals who recently died from counterfeit drugs were younger than 20 years old. The youngest recent victim is 14 years old, Denic said.
"You never know which line is going to kill you," he said, going back to the topic of cocaine.
Overdose symptoms
Jane Henderson, a harm reduction consultant with Newfoundland and Labrador Health Services, says harm reduction is an evidence-based approach that recognizes substance use is part of our communities and aims to reduce the consequences associated with it.
Harm reduction consultant Jane Henderson says anyone can experience a drug overdose. (Ted Dillon/CBC)
Henderson added the Good Samaritan Act legally protects people who seek emergency help during an overdose.
"Overdoses can happen to anyone," she said, and knowing the signs can save a life.
Signs may include:
Slow or no breathing,
Blue lips or fingertips,
Choking and gurgling sounds,
Unresponsiveness.
In the case of an opioid overdose, naloxone may help before emergency services arrive. Naloxone kits are free and readily available across the province, says Henderson.
Naloxone does not work for cocaine overdoses.
"To those of you who are using drugs, your life matters. You deserve safety, dignity and support," said Henderson.
"We understand that when abstinence is not realistic, there are ways for you to stay safer."
Download our free CBC News app to sign up for push alerts for CBC Newfoundland and Labrador. Click here to visit our landing page.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Psychedelic Science 2025 Unveils Science, Studies & Trials Tracks Showcasing Next Generation in Brain Imaging, Clinical Trials, and Neuroplasticity
• Sessions cover the latest updates in psychedelic neuroscience, from psilocybin's effects on brain connectivity to trial design, clinical outcomes for PTSD, depression, addiction, and OCD, and the future of drug development through translational models and AI innovations • Speakers include globally renowned experts like Gabrielle Agin-Liebes, Ph.D., Michael Bogenschutz, M.D., Robin Carhart-Harris, Ph.D., Alan K. Davis, Ph.D., Gül Dölen, M.D., Ph.D., Ben Kelmendi, M.D., Franklin King, M.D., Amy Lehrner, Ph.D., Leslie Morland, Psy.D., David Nutt, Ph.D., Stephen Ross, M.D., Emmanuelle Schindler, M.D., Ph.D., and Nolan Williams, M.D. • Representing institutions include Columbia, CU Denver, Imperial College London, Johns Hopkins, LSU, Massachusetts General Hospital, NYU, Ohio State, Stanford, UC Berkeley, UCSD, UCSF, University of Alabama, University of New Mexico, University of Washington, and numerous VA centers DENVER, June 11, 2025 (GLOBE NEWSWIRE) -- Psychedelic Science 2025 (PS2025), the world's leading conference on psychedelic research, medicine, policy, and culture hosted by the Multidisciplinary Association for Psychedelic Studies (MAPS), announced its Science, Studies, and Trials tracks—three of the conference's most anticipated and data-rich offerings. Taking place June 16–20, 2025, at the Colorado Convention Center in Denver, PS2025's research tracks will convene top clinical investigators, neuroscientists, biotech pioneers, and social scientists to present a comprehensive and cross-disciplinary view of this transformative field of study. At a time when the global mental health crisis continues to grow, PS2025 showcases therapeutic research using psychedelic compounds such as psilocybin, MDMA, LSD, DMT, 5-MeO-DMT, and ketamine, which are being investigated as treatments for serious mental illnesses such as addiction, depression, PTSD, obsessive-compulsive disorder, as well as neurological conditions such as pain, Alzheimer's, Lyme Disease, and Parkinson's. Beyond clinical trials, PS2025 also offers the latest in psychedelic neuroscience, examining data from studies using new neuroimaging, cellular, and molecular research tools that deepen the understanding of the biological mechanisms underlying their remarkable effects. Social science research is also included that examines the usage, attitudes, and experiences of trial participants, psychedelic consumers, and the general public, providing important context for societal views about this rapidly growing field. 'With the science and understanding of psychedelic substances expanding exponentially in recent years, we're honored to welcome some of the world's top academic researchers to PS2025 so they can share this new knowledge with attendees from around the globe.'— Philippe Lucas, Ph.D., Director, Research & Safe Access, MAPS The Science, Studies, and Trials tracks will feature both senior research leaders as well as emerging voices from public and private universities throughout North America, as well as international institutions in the UK, Europe, and Latin America. This highly anticipated convergence allows scientists to engage deeply about hot topics, including durability of efficacy, safety and risk, placebo dynamics, the role of psychotherapy, transdiagnostic effects, precision psychiatry, biological mechanisms, novel compounds, and the role of government grants and private capital in innovation. Visit to view the full schedule, register for workshops, and explore hotel and travel options. Workshop spaces are limited and available on a first-come basis. Featured sessions in the Science, Studies, and Trials tracks include:20 Years of Human Neuroscience Research with PsychedelicsDavid Nutt, Ph.D., reflects on two decades of pioneering work using brain imaging and neuropharmacology to explore consciousness, depression, and psychedelic mechanisms of action. Psychedelic Frontiers at the National Institutes of Health: NIH-funded Studies, Research Opportunities, and PrioritiesJoin a conversation moderated by Stacy Fischer, M.D., featuring Michael Bogenschutz, M.D., and Patrick Finan, Ph.D., as they unpack the latest NIH-funded studies, explore future research opportunities, and discuss the evolving priorities shaping this rapidly growing field of psychedelic-assisted therapy. Frontiers in Psilocybin Research for OCD: Neural Mechanisms, Treatment Response, and Clinical ImplicationsIn a session moderated by Jamila Hokanson, M.D., Ben Kelmendi, M.D., and Terence Ching, Ph.D., explore cutting-edge research on psilocybin's neural effects, clinical outcomes, and its potential as a treatment for OCD. Studies of Psychedelic-Assisted Therapy for Addiction DisordersJoin a conversation with Matthew Johnson, Ph.D., and Rayyan Zafar, Ph.D., moderated by Peter Hendricks, Ph.D., for a discussion on the latest research into the use of psychedelics as tools to treat addiction. This session will explore emerging evidence, clinical insights, and the challenges and promises of integrating psychedelic-assisted therapy into addiction treatment frameworks. Psychedelic Therapy for Military Veterans: A New Paradigm of Healing the Wounds of WarModerated by Chris Stauffer, M.D., and featuring Allie Kaigle, PharmD, BCPP, Amy Lehrner, Ph.D., and Leslie Morland, Psy.D., this session examines how psychedelic-assisted therapies are reshaping the landscape of care for Veterans grappling with PTSD, depression, and moral injury. By combining cutting-edge research with lived experience, these experts reveal how these innovative therapies can unlock hope, resilience, and lasting healing for those who have Outcomes from a Trial of Psilocybin-Assisted Therapy for Major Depressive DisorderIn this presentation, Alan K. Davis, Ph.D., shares groundbreaking findings from a long-term follow-up study examining the sustained effects of psilocybin-assisted therapy for individuals with major depressive disorder and what these results mean for the future of psychedelic treatments in mental health care. Ayahuasca: Bridging Molecular and Clinical Insights – A Multidisciplinary PanelDráulio Araújo, Ph.D., moderates a conversation with Fernanda Palhano-Fontes, Ph.D., Marcelo Falchi Parra Carvalho Silva, M.D., and Marcelo Leite, Ph.D., on the multifaceted world of ayahuasca through a unique convergence of molecular research, clinical practice, and traditional wisdom. The conversation offers insights into ayahuasca's molecular mechanisms and its applications in healing trauma and supporting personal growth. Developing Ibogaine for Opioid Use Disorder: Bridging Science, Public Benefit, and Sacred RootsSusan Ousterman moderates a conversation with Jeremy Weate, Ph.D., Ryan Rich, and Peter Hendricks, Ph.D., on the journey of ibogaine from traditional medicine to modern addiction therapy. Together, they'll explore clinical advancements, regulatory challenges, and how to ethically integrate indigenous knowledge and practices to address the opioid epidemic. Improving Standardization and Reducing Bias in Psychedelic Drug Development Trials Using an AI-Enabled PlatformJennifer Tippett, Psy.D., and Danielle Schlosser, Ph.D., discuss how artificial intelligence can transform psychedelic research by improving standardization, reducing bias, and enhancing data quality in clinical trials. Discover how this innovative approach is shaping the next generation of rigorous, ethical, and effective psychedelic drug development. The Potential for Psychedelic-Assisted Therapy in Conflict-Affected Populations: Ukraine and the BalkansModerated by Tadeusz Hawrot and featuring Oksana Gryshchenko, Elise Wilson, Zina Besirevic, Ph.D., and Galyna Pidpruzhnykova, Ph.D., this panel explores how psychedelic-assisted therapies might offer pathways to healing for individuals and communities affected by war and Differences in Therapeutic Outcomes Between Synthetic Psilocybin and Whole Psilocybe Mushrooms: A Qualitative StudyJoin Pamela Kryskow, M.D., and Joseph La Torre, Ph.D., as they present their qualitative study exploring the participants' lived experiences and perceptions, offering a deeper understanding of how these distinct forms of psilocybin influence healing, integration, and personal transformation. The Unique Challenges and Potential for Studying Psychedelic-Assisted Therapy for Palestinians and Jews in IsraelModerated by Keren Tzarfaty, Ph.D., MFT, and featuring Adar Avnon, Sidi Ronen, Ph.D., and Clinical Psychologist Wasim Biroumi, this session dives into the promise and complexities of researching psychedelic-assisted therapy in the unique socio-political landscape of Israel. The panel will discuss how shared trauma and cultural dynamics shape therapeutic approaches and the role psychedelics may play in fostering healing, understanding, and resilience across Outcomes from Yale's Real-World Psilocybin Trial: Connecticut-Funded Pioneering Psychedelic Therapy Program and Insights from Other State InitiativesJesse MacLachlan and Gabrielle Agin-Liebes, Ph.D., share findings from Yale's groundbreaking psilocybin trial, the first state-funded psychedelic therapy program in the U.S. This session will examine the transdiagnostic benefits observed in real-world settings and highlight key insights from Connecticut's initiative alongside other state-led programs shaping the future of psychedelic-assisted Critical Periods and Cephalopods: A Conversation with Neuroscientist Dr. Gül DölenJoin Gül Dölen, M.D., Ph.D., and Amy Emerson for a fascinating conversation that spans critical periods in brain development and the remarkable learning abilities of cephalopods. This session will illuminate the connections between these insights and the potential of psychedelics to re-open windows of plasticity in the adult brain. Listening to Lead: How a Community-Informed Psilocybin Study is Guiding New Mexico's Regulated ModelCrystal Romero, Janus Herrera, Dara Menashi, Ph.D., Larry Leeman, M.D., and Hanifa Nayo Washington (moderator) explore how New Mexico's historic Senate Bill 219 is paving the way for the nation's first state-regulated medical psilocybin program. This panel spotlights the community-informed pilot study by the Psychedelic Health Equity Initiative (PHEI), designed to center equity, accessibility, and culturally attuned care for underserved communities. Expanding the Lens: Mechanisms, Models & Modes - Transdiagnostic Potential of Psychedelic MedicinesJoin Charles Nichols, Ph.D., and Robin Carhart-Harris, Ph.D., as they unpack the unique mechanisms and models of action that position psychedelics as potential transdiagnostic treatments by addressing shared root causes across conditions. Treating Care Providers and Long COVID with Psychedelic-Assisted TherapyAnthony Back, M.D., moderates a vital discussion with Lawrence Purpura, M.D., Ph.D., Benjamin Lewis, M.D., Kush Bhatt, M.D., and Saleena Subaiya, M.D., on the emerging promise of psychedelic-assisted therapy to help those suffering from long COVID and the burnout experienced by care providers. This session will share clinical updates, innovative approaches, and new possibilities for fostering healing for those on the front lines of care. A Machine Learning Perspective on Psychedelics and PsychopathologyArthur Juliani, Ph.D., shares how artificial intelligence is revolutionizing clinical trial design, protocol optimization, and predictive modeling for psychedelic studies. From Rodents to Humans: Unlocking the Science of Psychedelic-Induced NeuroplasticityModerated by Lindsay Cameron, Ph.D., and featuring Manesh Girn, Ph.D., Max Vargas, Ph.D., and Neil Savalia, M.D./Ph.D(c), this session investigates the limitations of preclinical models in capturing the complexity of human psychedelic experiences and what these challenges mean for the future of psychedelic drug development. Psilocybin Desynchronizes the Human BrainJoin Joshua Siegel, M.D., Ph.D., as he delves into cutting-edge research exploring how psilocybin disrupts established patterns of brain connectivity – unpacking how these transient states of neural desynchronization might illuminate new pathways for therapeutic breakthroughs, and revealing the brain's remarkable flexibility and potential for healing. About Psychedelic SciencePsychedelic Science 2025 (PS2025), hosted by the Multidisciplinary Association for Psychedelic Studies (MAPS), is the world's leading psychedelic conference. Returning to the Colorado Convention Center in Denver from June 16-20, 2025, this five-day event brings together a global community of scientists, therapists, policymakers, cultural leaders, and advocates to explore the forefront of psychedelic research, therapy, and culture. Facilitated by Superfly, known for producing iconic events such as Bonnaroo and Outside Lands, PS2025 will feature expert speakers; hands-on workshops; community events with art, music, and mindfulness activities; and scholarship opportunities to support broad participation. Since its inception in 2010, the Psychedelic Science conference series has fostered knowledge-sharing, collaboration, and community-building within the psychedelic ecosystem. Join thousands of attendees as we explore the transformative potential of psychedelics and shape the future of mental health, policy, and cultural understanding. For more information and registration details, visit and follow us on X, Instagram, LinkedIn, and Facebook. ABOUT MAPSFounded in 1986, MAPS is a 501(c)(3) nonprofit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS' conference flagship, Psychedelic Science, has been the leading convening of the psychedelic community since 2010. MAPS incubated Lykos Therapeutics, a drug-development public benefit company, and the Zendo Project, a leader in psychedelic harm reduction. Since MAPS was founded, philanthropic donors and grantors have given more than $150 million to advance research, change drug policy, and evolve education in the field of psychedelics. CONTACTmedia@ while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
2 hours ago
- Yahoo
Family of woman seen dragged from police cruiser calling for justice
The family of a Smiths Falls, Ont., woman is demanding justice after a video surfaced online that appears to show the woman being dragged from a police cruiser and held to the ground after her arrest. The video, posted anonymously on social media, appears to show one of the officers dragging the handcuffed woman by her left leg from the back seat of Smiths Falls Police Service cruiser parked at a crosswalk. The officer then appears to pin the woman to the ground for about 20 seconds before pulling her to her feet and pushing her back into the car. Sarah Black, who told CBC she's the sister of the woman in the video, said she and her parents were distraught after seeing it. "It is absolutely heartbreaking to watch," Black told CBC. According to Smiths Falls police, the 29-year-old woman was arrested after officers were called to a business on Main Street E. where she was allegedly causing a disturbance, including acting belligerently and throwing a table against a wall. The same woman was suspected in an alleged assault that had occurred earlier that evening at a different location. Police said the woman was arrested and placed in the back of the cruiser where she began spitting and kicking a Plexiglas divider. The woman is facing one count each of causing a disturbance and uttering threats, and two counts each of mischief under $5,000, assaulting police and failure to comply with probation. She was scheduled to appear in court in Perth, Ont., on Wednesday. McKenzie LeClair has now come forward as the woman who captured the incident on video from a nearby window. "When I started recording I thought it was just going to be like any other arrest, and then I [saw] how the police officer handled her and my stomach just dropped," she said. LeClair posted the video on Facebook where it quickly gained traction and sparked outrage among some members of the local community. Black, who lives in California, said she heard about it from her mother. The family isn't contesting the woman's arrest, Black said, but they do want the police officers involved to be held accountable for how they handled the situation. "There is no reason that that kind of force was necessary in that scenario," said Black. Black explained her sister is a "complex person" who has a history of mental health and substance use issues that her family has been trying to help her manage for many years. "My sister needs help, not more trauma, and officers clearly need better training for mental health intervention if this is how they behave in these kinds of situations," Black said. "The officer should be ashamed." Smiths Falls police Chief Jodi Empey confirmed in a statement that she has been made aware of the video circulating on social media. Empey said both officers who appear in the video have been placed on administrative duties pending an investigation, which will be handled by a different police service. "We have determined this matter to be an institutional conflict and therefore must refer it to another police service for investigation," Empey said. Smiths Falls police would not confirm which service will investigate the incident, and said Empey would not be commenting further. Black said she and her family are awaiting the results of that investigation. "We want accountability — proper accountability including a full and fair investigation — and if found in the wrong, we want the officer or officers responsible to be charged or fired if necessary," she said.
San Francisco Chronicle
19 hours ago
- San Francisco Chronicle
NorCal man who sold pills to teen gets prison after fatal overdose
A Monterey County man was sentenced to eight years in prison for selling fentanyl-laced pills to a 15-year-old, leading to the minor's fatal overdose. Edward Tellez Solis, 27, pleaded guilty to possession with intent to distribute fentanyl, distribution of fentanyl and possession of a firearm in furtherance of a drug trafficking crime, the U.S. Attorney's Office in the Northern District of California announced Monday. Tellez Solis, of Marina (Monterey County), used social media to advertise and sell drugs, including counterfeit oxycodone pills, known as M30 pills, that were laced with fentanyl, the attorney's office said. Prosecutors said Tellez Solis also sold cocaine, ecstasy, hydrocodone, marijuana and Xanax. Law enforcement said Tellez Solis used Snapchat and Telegram to reach customers. 'Edward Tellez Solis used social media as a superhighway to sell lethal drugs and line his pockets with the proceeds,' Drug Enforcement Agency Special Agent in Charge Bob P. Beris said in a statement. On March 3, 2022, Tellez Solis offered to sell a 15-year-old more than a dozen M30 pills, prosecutors said, delivering at least nine of the pills to the teenager the next day. Prosecutors said Tellez Solis knew that the pills 'contained fentanyl or some other federally controlled substance.' The 15-year-old had an overdose and died after getting the M30 pills, the U.S. attorney's office said. Police searched Tellez Solis' car and found a 'stash of controlled substances,' as well as a loaded gun, three loaded magazines and 89 rounds of ammunition, prosecutors said. Law enforcement also found more than $17,000 in cash in Tellez Solis' car and nearly $100,000 in cash in his home, the attorney's office said. 'Today's sentencing marks a crucial step in bringing justice to the victim and a family devastated by the scourge of fentanyl,' Beris said. 'We will be relentless in our pursuit of unscrupulous drug dealers who distribute poison in our community.' On top of his prison time, Tellez Solis was also sentenced to three years of supervised release and ordered to pay nearly $30,000 to the family of the 15-year-old who fatally overdosed. 'While this sentence brings a measure of justice to the community for this crime, it can never undo the pain and devastation the defendant's reprehensible actions caused the victim's family,' United States Attorney Craig H. Missakian said in a statement.
